TSE:IN

InMed Pharmaceuticals - IN Stock Forecast, Price & News

Add

Compare

Today's Range: N/A
50-Day Range: C$4.19
▼
C$4.19
52-Week Range: N/A

Volume: 17,035 shs
Average Volume: 29,552 shs
Market Capitalization: C$33.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About InMed Pharmaceuticals (TSE:IN) Stock

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Receive IN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IN Stock News Headlines

January 24, 2023 | marketwatch.com

Global Blepharitis-Pipeline Market Size Growth Rate Analysis 2023 by Market Overview, Segments, Regions, Market Share and Forecast to 2028

January 4, 2023 | marketwatch.com

Thinking about buying stock in Geron Corp, InMed Pharmaceuticals, Kingsoft Cloud, Vivos Therapeutics, or Baozun?

January 27, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

December 14, 2022 | marketwatch.com

Spasticity Treatment Market Research Highlighting Global Opportunities 2023 | Growth Trends and Share Forecast to 2029

December 12, 2022 | nz.finance.yahoo.com

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

November 23, 2022 | msn.com

Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update

November 17, 2022 | finance.yahoo.com

InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program

November 16, 2022 | msn.com

Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session

January 27, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

November 16, 2022 | benzinga.com

Thinking about buying stock in Fast Radius, Camber Energy, InMed Pharmaceuticals, Taiwan Semiconductor, or Exela Technologies?

November 16, 2022 | msn.com

InMed stock rockets after research grant awarded for cannabinoid analogs to treat Alzheimer's, Parkinson's

November 12, 2022 | finanznachrichten.de

InMed Pharmaceuticals Inc.: InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update

November 12, 2022 | benzinga.com

InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update

September 30, 2022 | marketwatch.com

InMed Pharmaceuticals Shares Rise 30% on Higher-Than-Normal Volume

September 9, 2022 | nasdaq.com

InMed Pharma Gains 9%

August 25, 2022 | marketwatch.com

InMed Pharma to Consolidate Shares

August 25, 2022 | uk.investing.com

Here's Why InMed Pharmaceuticals Shares Are Getting Hammered Today

August 25, 2022 | seekingalpha.com

InMed Pharmaceuticals sinks 16% over consolidating 1 for 25 shares to meet listing requirements

July 25, 2022 | finance.yahoo.com

InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

July 18, 2022 | markets.businessinsider.com

InMed Pharma Names Michael Woudenberg As COO

June 14, 2022 | finance.yahoo.com

InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

June 9, 2022 | finance.yahoo.com

InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector

May 4, 2022 | finanznachrichten.de

Edison Investment Research Limited: InMed Pharmaceuticals : Notable Launches of High-Value Rare Cannabinoids

April 21, 2022 | baystreet.ca

This is Why Investors Are Excited About the Potential of Rare Cannabinoids

March 17, 2022 | benzinga.com

InMed Launching Additional Rare Cannabinoids In Response To Demand

March 17, 2022 | seekingalpha.com

InMed CFO steps down, interim CFO appointed

March 17, 2022 | nasdaq.com

InMed Pharma CFO Bruce Colwill To Retire - Quick Facts

See More Headlines

Receive IN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:IN
CUSIP: N/A
CIK: N/A
Web: www.inmedpharma.com
Phone: 604-669-7207
Fax: N/A
Employees: 12
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 8.48
Current Ratio: 2.13
Quick Ratio: 1.45

Sales & Book Value

Annual Sales: C$574,677.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 10.40
Book Value: C$0.76 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 8,051,000
Free Float: N/A
Market Cap: C$33.73 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Eric A. Adams (Age 58)
Pres, CEO & Director
Comp: $488.44k

Ms. Alexandra Diane-Janet Mancini (Age 69)
Sr. VP of Clinical & Regulatory Affairs
Comp: $337.13k

Dr. Sazzad Hossain M.Sc. (Age 64)
Ph.D., Co-Founder

Ms. Brenda Edwards C.M.A.
CPA, Interim Chief Financial Officer

Mr. Michael Woudenberg P.Eng. (Age 55)
Chief Operating Officer

Colin Clancy
Sr. Director of Investor Relations

Mr. Jerry P. Griffin
VP of Sales & Marketing

Dr. Eric Chih-Hsien Hsu (Age 52)
Sr. VP of Preclinical R&D

Dr. Shane A. Johnson Ph.D.
Sr. VP & GM of BayMedica

Dr. Ado Muhammad
Sr. Consultant of Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

Eric Ashley Adams
Bought 8,560 shares on 4/13/2022
Total: C$9,167.76 ($1.07/share)

View All Insider Transactions

IN Stock - Frequently Asked Questions

What other stocks do shareholders of InMed Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include Organigram (OGI), Aurora Cannabis (ACB), Canopy Growth (WEED), Baidu (BIDU), Cara Therapeutics (CARA), Copper Mountain Mining (CMMC), Corbus Pharmaceuticals (CRBP), HEXO (HEXO), InMed Pharmaceuticals (IMLFF) and Immunomedics (IMMU).
What is InMed Pharmaceuticals' stock symbol?: InMed Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IN."

How do I buy shares of InMed Pharmaceuticals?: Shares of IN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
How much money does InMed Pharmaceuticals make?: InMed Pharmaceuticals (TSE:IN) has a market capitalization of C$0.00 and generates C$574,677.00 in revenue each year.
How can I contact InMed Pharmaceuticals?: The official website for the company is www.inmedpharma.com. The company can be reached via phone at 604-669-7207.

This page (TSE:IN) was last updated on 1/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial